India News | Expert Panel Recommends Restricted Emergency Use Nod to Bharat Biotech's COVID-19 Vaccine
Get latest articles and stories on India at LatestLY. An expert panel of Drugs Controller General of India (DCGI) has recommended granting restricted emergency use authorisation to Bharat Biotech's indigenously developed COVID-19 vaccine, also known as Covaxin, government sources told ANI on Saturday.
By Priyanka Sharma
New Delhi [India], January 2 (ANI): An expert panel of Drugs Controller General of India (DCGI) has recommended granting restricted emergency use authorisation to Bharat Biotech's indigenously developed COVID-19 vaccine, also known as Covaxin, government sources told ANI on Saturday.
"Expert panel has recommended granting permission for restricted emergency use authorisation for Bharat Biotech's indigenously developed COVID-19 vaccine," a source said.
The meeting of Subject Expert Committee (SEC) meeting of Drugs Controller General of India (DCGI) was held in Delhi on Friday to review the application submitted by two companies - SII and Bharat Biotech- who had applied to get the emergency use authorisation (EUA) for their vaccine candidates.
Covaxin is an indigenously developed coronavirus vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR). (ANI)
(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)